Clinical trial Recruiting at 1 site Observational Ages 25 to 50 Women only

Sexual problems in women with relapsing-remitting multiple sclerosis

Official title: Sexual Dysfunction Prevalence and Its Relationship With Various Factors in Women With Multiple Sclerosis

Run by Ege University · NCT07193823 · Data updated 2026-11-12

See if sexual dysfunction is common in women aged 25-50 with relapsing-remitting MS and whether it's linked to fatigue, mood, bladder symptoms, and cognitive problems.

Quick facts

Study typeObservational
Ages25 Years to 50 Years
SexWomen only
Enrollment140 (estimated)
SponsorEge University
Academic / other
Locations1 site (Izmir, Bornova)
StatusRecruiting
StartedJuly 16, 2024
Main results expectedOctober 2025
Study endsNovember 2025
Registry record updatedSeptember 26, 2025
Trial IDNCT07193823 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 25–50 with relapsing-remitting MS, EDSS ≤5, literate, sexually active within the past 3 months, and with a continuous sexual partner are the ideal candidates.

Probably not a fit

Patients who are pregnant, have EDSS >5, are not sexually active or lack a regular partner, have high spasticity, or have non-relapsing forms of MS are unlikely to benefit from participating.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, clinic-based study of women 25–50 years old with relapsing-remitting MS who are sexually active and have EDSS ≤5. Participants complete validated questionnaires and brief cognitive testing including the FSFI for sexual function, BICAMS for cognition, HADS for anxiety and depression, FSS for fatigue, and OAB-V8 for bladder symptoms. The primary goal is to measure how common sexual dysfunction is in this group and the secondary goal is to look for statistical links between sexual dysfunction and fatigue, mood, bladder symptoms, and cognitive test results. Patients are recruited at the Neurology Department of Ege University in Izmir and must attend in-person visits.

Why it matters

Potential benefit: If successful, the findings could help clinicians recognize how common sexual dysfunction is in women with RRMS and prompt better screening and supportive care.

How similar studies have gone: Previous observational studies have frequently reported high rates of sexual dysfunction in women with MS and found links with fatigue, mood disorders, and bladder symptoms, so this approach builds on existing literature.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Female patients aged 25-50 years
* Literate and able to comprehend written and spoken instructions
* Diagnosed with relapsing-remitting form of multiple sclerosis
* Having a continuous/regular sexual partner
* Expanded Disability Status Scale (EDSS) score ≤ 5
* At least 3 months since the last relapse
* Sexually active within the past 3 months
* Spasticity level \< grade 2 according to the Modified Ashworth Scale

Exclusion Criteria:

* Pregnancy
* Illiteracy or inability to understand spoken or written instructions
* Absence of a continuous/regular sexual partner
* Expanded Disability Status Scale (EDSS) score \> 5
* Not sexually active within the past 3 months
* Spasticity level ≥ grade 2 according to the Modified Ashworth Scale

Where it's running

  • Ege University Faculty of Medicine, Department of Neurology
    Izmir, Bornova, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.